摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

ethyl (+/-)-3-amino-3-(3,5-dichlorophenyl)propanoate hydrochloride | 215738-51-5

中文名称
——
中文别名
——
英文名称
ethyl (+/-)-3-amino-3-(3,5-dichlorophenyl)propanoate hydrochloride
英文别名
ethyl 3-amino-3-(3,5-dichloro-phenyl)propionate hydrochloride;Ethyl 3-amino-3-(3,5-dichlorophenyl)propanoate hydrochloride;ethyl 3-amino-3-(3,5-dichlorophenyl)propanoate;hydrochloride
ethyl (+/-)-3-amino-3-(3,5-dichlorophenyl)propanoate hydrochloride化学式
CAS
215738-51-5
化学式
C11H13Cl2NO2*ClH
mdl
——
分子量
298.597
InChiKey
WTZLNIDVFBQYAB-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.37
  • 重原子数:
    17
  • 可旋转键数:
    5
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.36
  • 拓扑面积:
    52.3
  • 氢给体数:
    2
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    描述:
    ethyl (+/-)-3-amino-3-(3,5-dichlorophenyl)propanoate hydrochloride三乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 、 sodium hydroxide 作用下, 以 乙醇二氯甲烷 为溶剂, 反应 40.0h, 生成 3-(3,5-dichlorophenyl)-3-(5-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)pentanamido)propanoic acid
    参考文献:
    名称:
    Structure Activity Relationships of αv Integrin Antagonists for Pulmonary Fibrosis by Variation in Aryl Substituents
    摘要:
    Antagonism of alpha(v)beta(6) is emerging as a potential treatment of idiopathic pulmonary fibrosis based on strong target validation. Starting from an alpha(v)beta(3) antagonist lead and through simple variation in the nature and position of the aryl substituent, the discovery of compounds with improved alpha(v)beta(6) activity is described. The compounds also have physicochemical properties commensurate with oral bioavailability and are high quality starting points for a drug discovery program. Compounds 33S and 43E1 are pan av antagonists having ca. 100 nM potency against alpha(v)beta(3), alpha(v)beta(5), alpha(v)beta(6), and av beta 8 in cell adhesion assays. Detailed structure activity relationships with these integrins are described which also reveal substituents providing partial selectivity (defined as at least a 0.7 log difference in pIC(50) values between the integrins in question) for alpha(v)beta(3) and alpha(v)beta(5).
    DOI:
    10.1021/ml5002079
  • 作为产物:
    描述:
    参考文献:
    名称:
    Structure Activity Relationships of αv Integrin Antagonists for Pulmonary Fibrosis by Variation in Aryl Substituents
    摘要:
    Antagonism of alpha(v)beta(6) is emerging as a potential treatment of idiopathic pulmonary fibrosis based on strong target validation. Starting from an alpha(v)beta(3) antagonist lead and through simple variation in the nature and position of the aryl substituent, the discovery of compounds with improved alpha(v)beta(6) activity is described. The compounds also have physicochemical properties commensurate with oral bioavailability and are high quality starting points for a drug discovery program. Compounds 33S and 43E1 are pan av antagonists having ca. 100 nM potency against alpha(v)beta(3), alpha(v)beta(5), alpha(v)beta(6), and av beta 8 in cell adhesion assays. Detailed structure activity relationships with these integrins are described which also reveal substituents providing partial selectivity (defined as at least a 0.7 log difference in pIC(50) values between the integrins in question) for alpha(v)beta(3) and alpha(v)beta(5).
    DOI:
    10.1021/ml5002079
点击查看最新优质反应信息

文献信息

  • [EN] THE R-ISOMER OF BETA AMINO ACID COMPOUNDS AS INTEGRIN RECEPTOR ANTAGONISTS DERIVATIVES<br/>[FR] ISOMERE R DE COMPOSES D'ACIDES AMINES BETA EN TANT QUE DERIVES ANTAGONISTES DU RECEPTEUR DES INTEGRINES
    申请人:PHARMACIA CORPRATION
    公开号:WO2004060376A1
    公开(公告)日:2004-07-22
    The present invention relates to a class of compounds represented by the Formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula (I), and methods of selectively inhibiting or antagonizing the αVβ3 and/or the αV β5 integrin without significantly inhibiting the αV β6 integrin
    本发明涉及一类由公式(I)表示的化合物或其药用可接受的盐,包含公式(I)化合物的药物组合物,以及在不显著抑制αVβ6整合素的情况下选择性抑制或拮抗αVβ3和/或αVβ5整合素的方法。
  • Dihydrostilbene alkanoic acid derivatives
    申请人:——
    公开号:US20020099209A1
    公开(公告)日:2002-07-25
    The present invention relates to a class of compounds represented by the Formula 1. 1 or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula 1, and methods of selectively inhibiting or antagonizing the &agr; V &bgr; 3 and/or the &agr; V &bgr; 5 integrin.
    本发明涉及一类由化学式1.1表示的化合物或其药用可接受的盐,包括化合物1的制药组合物,以及选择性抑制或拮抗αVβ3和/或αVβ5整合素的方法。
  • An efficient new enzymatic method for the preparation of β-aryl-β-amino acid enantiomers
    作者:Gábor Tasnádi、Enikő Forró、Ferenc Fülöp
    DOI:10.1016/j.tetasy.2008.08.009
    日期:2008.9
    An efficient synthesis of β-aryl-β-amino acid enantiomers has been developed via the lipase-catalysed enantioselective hydrolysis of the corresponding racemic ethyl esters in an organic solvent. High enantioselectivities (E >100) were observed when the lipase PS-catalysed reactions were performed with H2O (0.5 equiv) in diisopropyl ether at 45 °C. The products could be easily separated and were obtained
    通过在有机溶剂中通过脂肪酶催化的相应外消旋乙酯的对映选择性水解,已经开发了β-芳基-β-氨基酸对映体的有效合成。当脂肪酶PS催化的H 2 O(0.5当量)在二异丙醚中于45°C进行时,观察到高对映选择性(E > 100)。产物易于分离,收率⩾40%。
  • [EN] META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS<br/>[FR] DERIVES DE LA META-GUANIDINE, DE L'UREE, DE LA THIO-UREE OU DE L'ACIDE AMINOBENZOIQUE AZACYCLIQUE UTILISES COMME ANTAGONISTES DE L'INTEGRINE
    申请人:G.D. SEARLE & CO.
    公开号:WO1997008145A1
    公开(公告)日:1997-03-06
    (EN) The present invention relates to a class of compounds represented by formula (I) or a pharmaceutically acceptable salt thereof, wherein A is (a) or (b) or (c) or (d) pharmaceutical compositions thereof and methods of using such compounds and compositions as $g(a)v$g(b)3 integrin antagonists.(FR) L'invention concerne une classe de composés représentés par la formule I et leurs sels acceptables sur le plan pharmaceutique. Dans cette formule, A est (a) ou (b) ou (c) ou (d). L'invention concerne également des préparations pharmaceutiques contenant ces composés, ainsi que des procédés d'utilisation de ces composés et de ces préparations comme antagonistes de l'intégrine $g(a)v$g(b)3.
    本发明涉及一类由公式(I)或其药学上可接受的盐所表示的化合物,其中A是(a)或(b)或(c)或(d),以及这些化合物和组合物作为$g(a)v$g(b)3整合素拮抗剂的药物组合物和使用方法。本发明还涉及包含这些化合物的药物制剂以及将这些化合物和制剂作为$g(a)v$g(b)3整合素拮抗剂的使用方法。
  • META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS
    申请人:G.D. SEARLE & CO.
    公开号:EP0850221B1
    公开(公告)日:2001-07-18
查看更多

同类化合物

(甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (R)-乙基N-甲酰基-N-(1-苯乙基)甘氨酸 (R)-丙酰肉碱-d3氯化物 (R)-4-N-Cbz-哌嗪-2-甲酸甲酯 (R)-3-氨基-2-苄基丙酸盐酸盐 (R)-1-(3-溴-2-甲基-1-氧丙基)-L-脯氨酸 (N-[(苄氧基)羰基]丙氨酰-N〜5〜-(diaminomethylidene)鸟氨酸) (6-氯-2-吲哚基甲基)乙酰氨基丙二酸二乙酯 (4R)-N-亚硝基噻唑烷-4-羧酸 (3R)-1-噻-4-氮杂螺[4.4]壬烷-3-羧酸 (3-硝基-1H-1,2,4-三唑-1-基)乙酸乙酯 (2S,3S,5S)-2-氨基-3-羟基-1,6-二苯己烷-5-N-氨基甲酰基-L-缬氨酸 (2S,3S)-3-((S)-1-((1-(4-氟苯基)-1H-1,2,3-三唑-4-基)-甲基氨基)-1-氧-3-(噻唑-4-基)丙-2-基氨基甲酰基)-环氧乙烷-2-羧酸 (2S)-2,6-二氨基-N-[4-(5-氟-1,3-苯并噻唑-2-基)-2-甲基苯基]己酰胺二盐酸盐 (2S)-2-氨基-3-甲基-N-2-吡啶基丁酰胺 (2S)-2-氨基-3,3-二甲基-N-(苯基甲基)丁酰胺, (2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺盐酸盐 (2R,3'S)苯那普利叔丁基酯d5 (2R)-2-氨基-3,3-二甲基-N-(苯甲基)丁酰胺 (2-氯丙烯基)草酰氯 (1S,3S,5S)-2-Boc-2-氮杂双环[3.1.0]己烷-3-羧酸 (1R,4R,5S,6R)-4-氨基-2-氧杂双环[3.1.0]己烷-4,6-二羧酸 齐特巴坦 齐德巴坦钠盐 齐墩果-12-烯-28-酸,2,3-二羟基-,苯基甲基酯,(2a,3a)- 齐墩果-12-烯-28-酸,2,3-二羟基-,羧基甲基酯,(2a,3b)-(9CI) 黄酮-8-乙酸二甲氨基乙基酯 黄荧菌素 黄体生成激素释放激素 (1-5) 酰肼 黄体瑞林 麦醇溶蛋白 麦角硫因 麦芽聚糖六乙酸酯 麦根酸 麦撒奎 鹅膏氨酸 鹅膏氨酸 鸦胆子酸A甲酯 鸦胆子酸A 鸟氨酸缩合物